Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 3/2016

Open Access 01-09-2016 | Review

A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management

Authors: Csaba Fehér, Josep Mensa

Published in: Infectious Diseases and Therapy | Issue 3/2016

Login to get access

Abstract

Clostridium difficile infection (CDI) is increasingly recognized as an emerging healthcare problem of elevated importance. Prevention and treatment strategies are constantly evolving along with the apperance of new scientific evidence and novel treatment methods, which is well-reflected in the differences among consecutive international guidelines. In this article, we summarize and compare current guidelines of five international medical societies on CDI management, and discuss some of the controversial and currently unresolved aspects which should be addressed by future research.
Appendix
Available only for authorised users
Literature
1.
Argamany JR, Aitken SL, Lee GC, Boyd NK, Reveles KR. Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010. Am J Infect Control. 2015;43:435–40.PubMedCrossRef
2.
3.
Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84.PubMedCrossRef
4.
Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:381–90.PubMedCrossRef
5.
Magee G, Strauss ME, Thomas SM, Brown H, Baumer D, Broderick KC. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: a multicenter retrospective study of inpatients, 2009–2011. Am J Infect Control. 2015;43:1148–53.PubMedCrossRef
6.
Gao T, He B, Pan Y, et al. Association of Clostridium difficile infection in hospital mortality: a systematic review and meta-analysis. Am J Infect Control. 2015;43:1316–20.PubMedCrossRef
7.
Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of Clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofv186.PubMedCrossRef
8.
Chakra CNA, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE. 2012;7:e30258.PubMedPubMedCentralCrossRef
9.
Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32:220–8.PubMedCrossRef
10.
Gomez-Simmonds A, Kubin CJ, Furuya EY. Comparison of 3 severity criteria for Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;35:196–9.CrossRef
11.
Khanafer N, Barbut F, Eckert C, et al. Factors predictive of severe Clostridium difficile infection depend on the definion used. Anaerobe. 2015;37:43–8.PubMedCrossRef
12.
Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31:21–7.PubMedCrossRef
13.
Ferrada P, Velopulos CG, Sultan S, et al. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2014;76:1484–93.PubMedCrossRef
14.
Goyal H, Singla U. Infectious diseases society of America or American college of gastroenterology guidelines for treatment of Clostridium difficile infection: which one to follow? Am J Med. 2015;128:e17.PubMedCrossRef
15.
Curtin BF, Zarbalian Y, Flasar MH, von Rosenvinge E. Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center. World J Gastroenterol. 2013;19:8647–51.PubMedPubMedCentralCrossRef
16.
Wieczorkiewicz S, Zatarski R. Adherence to and outcomes associated with a Clostridium difficile guideline at a large teaching institution. Hosp Pharm. 2015;50:42–50.PubMedPubMedCentralCrossRef
17.
Rodríguez-Martín C, Serrano-Morte A, Sánchez-Muñoz LA, de Santos-Castro PA, Bratos-Pérez MA, Ortiz de Lejarazu-Leonardo R. Diferencias entre las recomendaciones y la práctica clínica en la infección por Clostridium difficile. Rev Calid Asist. 2015. doi:10.​1016/​j.​cali.​2015.​09.​009.PubMed
18.
Aguado JM, Anttila VJ, Galperine T, et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015;90:117–25.PubMedCrossRef
19.
Martin M, Zingg W, Knoll E, et al. National European guidelines for the prevention of Clostridium difficile infection: a systematic qualitative review. J Hosp Infect. 2014;87:212–9.PubMedCrossRef
20.
21.
Hernández-rocha C, Pidal P, Ajenjo MC, et al. Consenso chileno de prevención, diagnóstico y tratamiento de la diarrea asociada a Clostridium difficile. Rev Chilena Infectol. 2016;33:98–118.
22.
Beneš J, Husa P, Nyč O, Polívková S. Diagnosis and therapy of Clostridium difficile infection: Czech national guidelines. Klin Mikrobiol infekc̆ní lékar̆ství. 2014;20:56–66.
23.
Sokol H, Galperine T, Kapel N, et al. Faecal microbiota transplantation in recurrent Clostridium difficile infection: recommendations from the French Group of Faecal microbiota transplantation. Dig Liver Dis. 2016;48:242–7.PubMedCrossRef
24.
25.
Vehreschild MJGT, Vehreschild JJ, Hübel K, et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the infectious diseases working party (AGIHO) of the german society of hematology and oncology (DGHO). Ann Oncol. 2013;24:1189–202.PubMedCrossRef
26.
Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.PubMedCrossRef
27.
Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.PubMedCrossRef
28.
Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.PubMedCrossRef
29.
Sartelli M, Malangoni MA, Abu-Zidan FM, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38.PubMedPubMedCentralCrossRef
30.
Cheng AC, Ferguson JK, Richards MJ, et al. Australasian society for infectious diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust. 2011;194:353–8.PubMed
31.
Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J. 2016;46:479–93.PubMedCrossRef
32.
Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect. 2008;14:2–20.PubMedCrossRef
33.
Stuart RL, Mbbs CM, Dip G, et al. ASID/AICA position statement—infection control guidelines for patients with Clostridium difficile infection in healthcare settings. Healthc Infect. 2011;16:33–9.CrossRef
34.
Greenfield C, Szawathowski M, Noone P, Burroughs A, Bass N, Pounder R. Is pseudomembranous colitis infectious? Lancet. 1981;317:371–2.CrossRef
35.
Shrestha SK, Sunkesula VCK, Kundrapu S, Tomas ME, Nerandzic MM, Donskey CJ. Acquisition of Clostridium difficile on hands of healthcare personnel caring for patients with resolved C. difficile infection. Infect Control Hosp Epidemiol. 2016;37:475–7.PubMedCrossRef
36.
Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis. 2012;31:3163–71.PubMedPubMedCentralCrossRef
37.
Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized patients with cirrhosis should be screened for Clostridium difficile Colitis. Dig Dis Sci. 2015;60:3124–9.PubMedCrossRef
38.
Grigoras CA, Zervou FN, Zacharioudakis IM, Siettos CI, Mylonakis E. Isolation of C. difficile carriers alone and as part of a bundle approach for the prevention of Clostridium difficile infection (CDI): a mathematical model based on clinical study data. PLoS One. 2016;11:e0156577.PubMedPubMedCentralCrossRef
39.
Longtin Y, Paquet-Bolduc B, Gilca R, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C. difficile infections. JAMA. Intern Med. 2016;. doi:10.​1001/​jamainternmed.​2016.​0177.
40.
Sunkesula VCK, Kundrapu S, Muganda C, Sethi AK, Donskey CJ. Does empirical Clostridium difficile infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin Infect Dis. 2013;57:494–500.PubMedCrossRef
41.
Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–801.PubMedPubMedCentralCrossRef
42.
Chakra CNA, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE. 2014;9:e98400.PubMedPubMedCentralCrossRef
43.
Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63–73.PubMedCrossRef
44.
Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis. 2009;15:415–22.PubMedPubMedCentralCrossRef
45.
Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53:1173–8.PubMedCrossRef
46.
Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583–9.PubMedCrossRef
47.
Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect. 2011;79:359–63.PubMedCrossRef
48.
Bhangu S, Bhangu A, Nightingale P, Michael A. Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. Color Dis. 2010;12:241–6.CrossRef
49.
Marra AR, Edmond MB, Wenzel RP, Bearman GML. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 2007;7:42.PubMedPubMedCentralCrossRef
50.
Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis. 2009;48:568–76.PubMedCrossRef
51.
Pépin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRef
52.
Rao K, Micic D, Chenoweth E, et al. Decreased functional status as a risk factor for severe Clostridium difficile infection among hospitalized older adults. J Am Geriatr Soc. 2013;61:1738–1742.
53.
Kim ES, Kim YJ, Park CW, et al. Response failure to the treatment of Clostridium difficile infection and its impact on 30-day mortality. Hepatogastroenterology. 2013;60:543–8.PubMed
54.
Kassam Z, Cribb Fabersunne C, Smith MB, et al. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther. 2016;43:725–33.PubMedCrossRef
55.
Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Mahaparn P, Bruminhent J. High mortality risk in chronic kidney disease and end stage kidney disease patients with Clostridium difficile infection: a systematic review and meta-analysis. J Nat Sci. 2015;73:389–400.
56.
Cober ED, Malani PN. Clostridium difficile infection in the ‘“oldest”’ old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc. 2009;57:659–62.PubMedCrossRef
57.
Wenisch JM, Schmid D, Kuo HW, et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis. 2012;31:1923–30.PubMedCrossRef
58.
Wilson V, Cheek L, Satta G, et al. Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis. 2010;50:e77–81.PubMedCrossRef
59.
Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery. 2008;143:623–9.PubMedCrossRef
60.
Negrón ME, Rezaie A, Barkema HW, et al. Ulcerative colitis patients with Clostridium difficile are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study. Am J Gastroenterol. 2016;111:691–704.PubMedCrossRef
61.
Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106–13.PubMedCrossRef
62.
Hardt C, Berns T, Treder W, Dumoulin FL, Hardt C, Dumoulin FL. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein. World J Gastroenterol. 2008;14:4338–41.PubMedPubMedCentralCrossRef
63.
Cadena J, Thompson GR, Patterson JE, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci. 2010;339:350–5.PubMedCrossRef
64.
Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040–9.PubMedCrossRef
65.
Archbald-Pannone LR, McMurry TL, Guerrant RL, Warren CA. Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients. Am J Infect Control. 2015;43:690–3.PubMedPubMedCentralCrossRef
66.
Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AMC. difficile colitis-predictors of fatal outcome. J Gastrointest Surg. 2010;14:315–22.PubMedCrossRef
67.
Arora V, Kachroo S, Ghantoji SS, DuPont HL, Garey KW. High Horn’s index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011;79:23–6.PubMedCrossRef
68.
69.
Boland GW, Lee MJ, Cats AM, Ferraro MJ, Matthia AR, Mueller PR. Clostridium difficile colitis: correlation of CT findings with severity of clinical disease. Clin Radiol. 1995;50:153–6.PubMedCrossRef
70.
Ash L, Baker ME, O’Malley CM, Gordon SM, Delaney CP, Obuchowski NA. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: Prevalence and significance of findings. Am J Roentgenol. 2006;186:1393–400.CrossRef
71.
Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut. 2004;53:673–7.PubMedPubMedCentralCrossRef
72.
Tang DM, Urrunaga NH, von Rosenvinge EC. Pseudomembranous colitis: not always Clostridium difficile. Cleve Clin J Med. 2016;83:361–6.PubMed
73.
Berdichevski T, Keller N, Rahav G, Bar-Meir S, Eliakim R, Ben-Horin S. The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease. Infection. 2013;41:969–77.PubMedCrossRef
74.
Rokas K, Johnson J, Beardsley J, Ohl C, Luther V, Williamson J. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934–41.PubMedCrossRef
75.
Erikstrup LT, Aarup M, Hagemann-Madsen R, et al. Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol. 2015;2:e000038.PubMedPubMedCentralCrossRef
76.
Li R, Lu L, Lin Y, Wang M, Liu X. Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0137252.PubMedPubMedCentralCrossRef
77.
Garey KW, Sethi S, Yadav Y, Dupont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRef
78.
Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:452–60.PubMedCrossRef
79.
Abdelfatah M, Nayfe R, Nijim A, et al. Factors predicting recurrence of Clostridium difficile infection (CDI) in hospitalized patients: retrospective study of more than 2000 patients. J Investig Med. 2015;63:747–51.PubMedCrossRef
80.
Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, et al. First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis. Eur J Clin Microbiol Infect Dis. 2016;35:371–8.PubMedCrossRef
81.
McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175:784–94.PubMedCrossRef
82.
Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;. doi:10.​1038/​ajg.​2016.​187.PubMed
83.
Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107:1011–9.PubMedCrossRef
84.
Novack L, Kogan S, Gimpelevich L, et al. Acid suppression therapy does not predispose to Clostridium difficile Infection: the case of the potential bias. PLoS ONE. 2014;9:e110790.PubMedPubMedCentralCrossRef
85.
Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015;2:e000028.PubMedPubMedCentralCrossRef
86.
Musa S, Thomson S, Cowan M, Rahman T. Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol. 2010;45:261–72.PubMedCrossRef
87.
Callejas-Díaz A, Gea-Banacloche JC. Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation. Curr Hematol Malig Rep. 2014;9:85–90.PubMedCrossRef
88.
Chilton CH, Crowther GS, Todhunter SL, et al. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2015;. doi:10.​1093/​jac/​dkv156.PubMedCentral
89.
Venugopal AA, Riederer K, Patel SM, et al. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Scand J Infect Dis. 2012;44:243–9.PubMedCrossRef
90.
Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection. 2016;. doi:10.​1007/​s15010-016-0894-y.PubMed
91.
Lapointe-Shaw L, Tran KL, Coyte PC, et al. Cost-effectiveness analysis of six strategies to treat recurrent Clostridium difficile infection. PLoS ONE. 2016;11:e0149521.PubMedPubMedCentralCrossRef
92.
Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:7007–10.PubMedPubMedCentralCrossRef
93.
Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IAO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014;69:2901–12.PubMedPubMedCentralCrossRef
94.
Goldenberg S, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35:251–9.PubMedCrossRef
95.
Biswas JS, Patel A, Otter JA, et al. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. J Hosp Infect. 2015;90:267–70.PubMedCrossRef
96.
Deshpande A, Hurless K, Cadnum JL, et al. Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2016;. doi:10.​1128/​AAC.​02590-15.
97.
Maseda E, Hernandez-Gancedo C, Lopez-Tofiño A, Suarez-de-la-Rica A, Garcia-Bujalance S, Gilsanz F. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit. Rev Esp Quimioter. 2013;26:375–7.PubMed
98.
Peju E, Arcizet J, Fillion A, Chavanet P, Prudent C, Piroth L. Multiple recurrences of Clostridium difficile infection treated with crushed fidaxomicin administered through a percutaneous endoscopic gastrostomy tube. Ann Pharmacother. 2015;49:853–4.PubMedCrossRef
99.
Tousseeva A, Jackson JD, Redell M, et al. Stability and recovery of DIFICID® (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D. 2014;14:309–14.PubMedPubMedCentralCrossRef
100.
Lewis BB, Buffie CG, Carter RA, et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis. 2015;212:1656–65.PubMedCrossRef
101.
Kapel N, Thomas M, Corcos O, Mayeur C, Bouhnik Y, Joly F. Practical implementation of faecal transplantation. Clin Microbiol Infect. 2014;20:1098–105.PubMedCrossRef
102.
Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A, Coli E. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–7.PubMedCrossRef
103.
Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis. 2016;62:908–14.PubMedCrossRef
104.
Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;. doi:10.​1111/​apt.​13144 (Epub ahead of print).
105.
Varier RU, Biltaji E, Smith KJ, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36:438–44.PubMedCrossRef
106.
Merlo G, Graves N, Brain D, Connelly L. Economic evaluation of fecal microbiota transplantation for the treatment of recurrenc Clostridium difficile infection in Australia. J Gastroenterol Hepatol. 2016;. doi:10.​1111/​jgh.​13402.PubMed
107.
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8.PubMedCrossRef
108.
Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.PubMedPubMedCentral
109.
Gerding DN, Kelly C, Rahav G, et al. Efficacy of bezlotoxumab, the monoclonal antibody targeting C. difficile toxin B, for prevention of C. difficile infection (CDI) recurrence in patients at high risk of recurrence or CDI-related adverse outcomes. In: European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam; 2016.
110.
de Bruyn G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized Phase 2 clinical trial. Vaccine. 2016;34:2170–8.PubMedCrossRef
111.
Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423–7.PubMedCrossRef
112.
Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Color Dis. 2013;15:798–804.CrossRef
113.
Kautza B, Zuckerbraun BS. The surgical management of complicated Clostridium Difficile infection: alternatives to colectomy. Surg Infect (Larchmt). 2016;17:337–42.CrossRef
Metadata
Title
A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management
Authors
Csaba Fehér
Josep Mensa
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0122-1

Other articles of this Issue 3/2016

Infectious Diseases and Therapy 3/2016 Go to the issue

Review

Clostridium difficile Infection in Special High-Risk Populations

Erratum

Erratum to: In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study

Review

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need

Review

Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review

Erratum

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Original Research

Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits